The Cigna Group (CI) Barclays 27th Annual Global Healthcare Conference (Transcript)
Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...
pharmaphorum2d
Rova-T: the story of AbbVie’s multi-billion dollar failure
Rova-T had a convincing-looking mechanism of action ... were in the region of $5 billion per year at peak. It wasn’t a Humira, but AbbVie was realistic enough to accept that it was unlikely ...
DelveInsight Business Research, LLP: Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Investing5d
Roivant at Leerink’s Conference: Strategic Insights and Developments
Humira is approved and some biologics are used ... 1b data showing really the deepest PVR improvements shown across any mechanism of drug in Group one PAH patients and we’re now running a ...
pharmaphorum3d
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
The $45-per-share agreement gives AbbVie a pipeline of CNS drugs headed by emraclidine (formerly CVL-231), a drug for schizophrenia with a new mechanism of action that could offer reduced side ...
Investing5d
Roivant at Leerink’s Conference: Strategic Insights and Developments
Humira is approved and some biologics are used off label ... really strong kind of Phase 1b data showing really the deepest PVR improvements shown across any mechanism of drug in Group one PAH ...